March 1, 2019

NeuroCycle Therapeutics Awarded NIH SBIR Grant to Study Next-Generation Treatment of Dravet Syndrome

NeuroCycle Therapeutics, Inc. announced it had been awarded a $0.5M Small Business Innovation Research grant from the National institute of Neurological Disorders and Stroke (NINDS) to evaluate its advanced subtype-selective GABAA receptor modulators, NCT10004 and NCT10015, in models of Dravet Syndrome (Award Number R43NS107051).

This grant builds upon the company’s strategy to develop a portfolio of small molecule drug candidates that maximize efficacy and minimize side effects through selective targeting of the central nervous system.

Related News

January 12, 2024

Seizures Identified as Potential Cause of Sudden Unexplained Deaths in Children

“These findings show that seizures are much more common than patients’ medical histories suggest, and that further research is needed to determine if seizures are frequent occurrences in sleep-related deaths in toddlers, and potentially in infants, older children, and adults,”

August 29, 2023

Early Treatment with Vigabatrin Does Not Decrease Focal Seizures or Improve Cognition in Tuberous Sclerosis Complex: The PREVeNT Trial

 Preventative treatment with vigabatrin based on EEG epileptiform activity prior to seizure onset does not improve neurocognitive outcome at 24 months in TSC children.

July 3, 2023

Sleep Problems in Adolescents with Epilepsy and their Caregivers: Associations with Behavioral Difficulties

Researchers investigate the frequency of sleep problems in adolescents with epilepsy and their caregivers.